Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia
First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically ...
9 hours ago
0
1